Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 14/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1322760 | 0.88 | MDM2 (0.56) | MDM2TP53MEN1KMT2A | |
| SCHEMBL1321538 | 0.88 | MDM2 (0.51) | MDM2TP53EPHX2 | |
| SCHEMBL3243048 | 0.88 | MDM2 (0.51) | MDM2TP53 | |
| SCHEMBL1325985 | 0.87 | MDM2 (0.55) | MDM2TP53MEN1KMT2A | |
| SCHEMBL1319816 | 0.87 | MDM2 (0.50) | MDM2TP53 | |
| SCHEMBL3250970 | 0.86 | MDM2 (0.49) | MDM2TP53KMT2AEPHX2 | |
| SCHEMBL12121928 | 0.86 | MDM2 (0.52) | MDM2TP53MEN1KMT2A | |
| SCHEMBL27875552 | 0.84 | MDM2 (0.51) | MDM2TP53KMT2A | |
| SCHEMBL27875551 | 0.84 | MDM2 (0.51) | MDM2TP53ACKR3EPHX2 | |
| SCHEMBL1319803 | 0.84 | MDM2 (0.49) | MDM2TP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516366-B | Oxindole derivatives as anticancer agents | HOFFMANN LA ROCHE | 2012-05-30 | — | — | CN | claimed |
| US-8058269-B2 | rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins | HOFFMAN-LA ROCHE INC. (US) | 2011-11-15 | — | — | US | claimed |
| EP-2066318-B1 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | claimed |
| CN-101516366-A | Oxindole derivatives as anticancer agents | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | claimed |
| US-20080081810-A1 | OXINDOLE DERIVATIVES | CHEN LI | 2008-04-03 | — | — | US | claimed |
| CN-101516366-B | Oxindole derivatives as anticancer agents | HOFFMANN LA ROCHE | 2012-05-30 | — | — | CN | disclosed |
| US-8058269-B2 | rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins | HOFFMAN-LA ROCHE INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2066318-B1 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | disclosed |
| EP-2066318-B1 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | disclosed |
| CN-101516366-A | Oxindole derivatives as anticancer agents | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-2066318-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080081810-A1 | OXINDOLE DERIVATIVES | CHEN LI | 2008-04-03 | — | — | US | disclosed |
| WO-2008034736-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008034736-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081810-A1 | OXINDOLE DERIVATIVES | CCNY, CCNI, RPS4Y1 | MDM2 441/4885TP53 219/4885ACKR3 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.